Lactoferrin Use in ICU Patients

Launched by MANSOURA UNIVERSITY HOSPITAL · Jul 6, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of lactoferrin, a natural substance known for its health benefits, on patients in the Intensive Care Unit (ICU). Researchers want to see if lactoferrin can help improve the health outcomes of these patients compared to a placebo, which is a treatment that has no active ingredients. The trial will involve 650 patients who are admitted to the ICU at Mansoura University Hospital, and it is designed to be fair and unbiased by using a method called randomization.

To be eligible for the trial, patients of any age and gender who are admitted to the ICU can participate, as long as they do not have certain conditions like milk allergies or lactose intolerance. They also need to be able to provide consent or have a family member do so for them. Participants will be divided into two groups: one will receive lactoferrin, and the other will receive the placebo. Throughout the trial, both the patients and the healthcare providers will not know who is receiving which treatment to keep the results impartial. This study aims to determine not just if lactoferrin is effective, but also if it is safe for patients in critical condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The inclusion criteria for patients to participate in this research include adult (age ≥ 18 years) patients admitted to ICU for any reason or disease.
• Exclusion Criteria:
• • inability to give informed consent by patients or their relative,
• • history of hypersensitivity to milk products,
• • history of lactoferrin use in the past 6 months,
• • patients with lactose intolerance,
• • patients with no enteral access to administer LF either orally or by Ryle tube,
• • patients who are expected to die within 48 hours, and
• • patients with poor oral absorption as in case of shock and resected bowel.